Nur Nicholson Sells 7,725 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 7,725 shares of the business’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $168,173.25. Following the transaction, the insider owned 71,118 shares of the company’s stock, valued at $1,548,238.86. The trade was a 9.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Nur Nicholson also recently made the following trade(s):

• On Tuesday, January 20th, Nur Nicholson sold 2,203 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $19.79, for a total transaction of $43,597.37.
• On Tuesday, January 13th, Nur Nicholson sold 2,618 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $22.19, for a total value of $58,093.42.

Apellis Pharmaceuticals Stock Down 1.1%

Shares of NASDAQ APLS traded down $0.25 during mid-day trading on Friday, reaching $21.76. 2,214,978 shares of the company’s stock were exchanged, compared to its average volume of 3,258,745. Apellis Pharmaceuticals, Inc. has a twelve month low of $16.10 and a twelve month high of $30.91. The company has a current ratio of 3.54, a quick ratio of 3.10 and a debt-to-equity ratio of 0.90. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of 70.18 and a beta of 0.31. The business has a fifty day simple moving average of $22.99 and a 200 day simple moving average of $23.49.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The business had revenue of $458.58 million during the quarter, compared to analysts’ expectations of $364.58 million. During the same period in the prior year, the business earned ($0.46) EPS. Apellis Pharmaceuticals’s revenue for the quarter was up 133.0% compared to the same quarter last year. As a group, equities analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on APLS shares. Wells Fargo & Company dropped their price target on Apellis Pharmaceuticals from $29.00 to $26.00 and set an “overweight” rating on the stock in a research note on Tuesday. Cantor Fitzgerald decreased their price objective on Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating for the company in a report on Tuesday, January 13th. The Goldman Sachs Group restated a “sell” rating and issued a $19.00 target price on shares of Apellis Pharmaceuticals in a research note on Monday, January 12th. Needham & Company LLC cut their price objective on shares of Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating on the stock in a research report on Tuesday, January 13th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Apellis Pharmaceuticals in a research report on Monday, December 29th. Twelve equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $33.53.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Parallel Advisors LLC raised its position in shares of Apellis Pharmaceuticals by 80.0% in the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock valued at $33,000 after purchasing an additional 855 shares during the period. Jones Financial Companies Lllp raised its holdings in Apellis Pharmaceuticals by 206.8% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock valued at $46,000 after acquiring an additional 1,373 shares during the period. Allworth Financial LP grew its position in shares of Apellis Pharmaceuticals by 64.1% in the third quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after purchasing an additional 857 shares during the last quarter. Osaic Holdings Inc. grew its position in shares of Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after purchasing an additional 1,570 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in Apellis Pharmaceuticals during the 3rd quarter worth approximately $64,000. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals News Roundup

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS to Buy and cited a stronger-than-expected launch trajectory for Apellis’s newly approved kidney-disease therapy, assigning a $28 price target — a vote of confidence that implies material upside if commercial momentum continues. Apellis Raised to Buy at Bank of America
• Positive Sentiment: An analyst note highlights early uptake of Empaveli and argues current valuation understates its revenue potential; continued strong launch metrics could drive a re‑rating and support upside from current levels. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (from $29 to $26) but kept an Overweight rating — a mixed signal that reduces upside expectations while leaving institutional support intact. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, a neutral stance that may temper buying interest from investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Multiple senior insiders — including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others — filed Form 4 sales on Jan. 20–22 (large, clustered disposals totaling many tens of thousands of shares). Even if routine (diversification or option-related), clustered executive selling typically weighs on near‑term sentiment and likely contributed to the stock decline. See CEO filing for details. CEO Cedric Francois Form 4

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.